← Leaderboards
Graciela L Lorca
University Of Florida
$3,239,920
Attributed
$3,495,773
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $656.6K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,495,773 · 3
By mechanism
R01$2,838,299 · 1
R56$511,706 · 1
R03$145,768 · 1
Top collaborators
- Leslie A Parker1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Leslie A Parker$4,423,611
- Arnold Louie$12,883,478
- George Louis Drusano$18,475,919
- Jennifer Jane Schoch$484,704
- Josef Neu$3,430,847
Others in their field
Top investigators on “Bacteria”
- James E. Gern · University Of Wisconsin-Madison$138,333,846
- Ian A Wilson · Scripps Research Institute, The$90,122,969
- Vance G Fowler · Duke University$85,101,521
- Henry F Chambers · Duke University$84,838,080
- Timothy Henkel · Venatorx Pharmaceuticals, Inc.$48,397,895
- David Alland · Rutgers Biomedical And Health Sciences$47,292,355
Research focus
BacteriaEnvironmentLactobacillusImmune ResponseFrequenciesMicrobialImmunityDysbiosisAdultIntestinesC-PeptideCell TypeBeta CellConsumptionBifidobacteriumChildCulture-Independent MethodsCell LineAdverse EffectsCd8-Positive T-LymphocytesAnimalsBaseBeneficial MicroorganismCell Physiology
Grant awards (8)
Frequent Standardized Oral Care Using Human Milk to Reduce Gastrointestinal Dysbiosis and Inflammation to Improve Health Outcomes and Reduce Cost in Preterm Very Low Birth Weight Infants$511,706
R56 · FY2025 · DE
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1$472,326
R01 · FY2024 · DK · contact PI
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1$492,005
R01 · FY2023 · DK · contact PI
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1$656,579
R01 · FY2021 · DK · contact PI
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1$578,531
R01 · FY2020 · DK · contact PI
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1$638,858
R01 · FY2019 · DK · contact PI
Identification of New Lactobacillus Regulators Responsive to FDA-Approved Drugs$72,518
R03 · FY2010 · AI · contact PI
Identification of New Lactobacillus Regulators Responsive to FDA-Approved Drugs$73,250
R03 · FY2009 · AI · contact PI